SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense volatility and a massive sell-off after Marvell canceled purchase orders linked to Celestial AI, citing a confidentiality breach by management. The community is sharply divided between investors demanding management accountability for the delayed disclosure of this news and those betting on a recovery based on the company's underlying optical technology.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is experiencing intense selling pressure and record-low valuations, leaving investors deeply divided between those viewing the current price as a long-term bargain due to PIF and Uber backing and those fearing further dilution, a potential reverse split, or even bankruptcy. The community is heavily focused on the disconnect between the company's high-performance vehicle technology and its ongoing struggle to sustain share price momentum amid persistent capital burn.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is capturing significant community attention following the successful completion of historic point-to-point air taxi demonstration flights in New York City. Investors are closely monitoring the company's transition from prototype testing to real-world infrastructure integration as they progress through critical FAA certification phases.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science SA is trending due to significant retail interest surrounding its low-float status, which market participants are actively discussing as a primary catalyst for potential short-squeeze activity. The community is sharply divided, with bulls pointing to the company's molecular farming technology as a long-term play, while bears express skepticism regarding its underlying financials and the risk of being left as 'exit liquidity' in what they label a pump-and-dump scheme.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is seeing heightened activity as investors weigh recent reports of revenue growth and operational improvements against ongoing concerns about cash burn and a challenging retail environment. The community remains deeply divided, with some traders focused on potential squeeze setups and the company's long-term turnaround strategy, while others emphasize the stock's significant decline and persistent volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is surging to new all-time highs as massive institutional liquidity continues to concentrate in the stock, solidifying its position as the primary infrastructure backbone of the AI sector. While some market participants debate potential overvaluation or volatility risks, the community is heavily focused on the company's compounding dominance, sustained capex demand, and the strength of the bullish momentum leading into upcoming earnings.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant volatility and community interest, driven by its role as a leading decentralized exchange on Solana and speculation regarding DAO-led buyback programs. Traders are actively debating its potential for a short squeeze and price appreciation, while monitoring its performance against broader market movements and platform integrations.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing significant momentum and extreme volatility, with the community actively debating whether the move is a sustainable squeeze or a high-risk pump and dump. Traders are closely monitoring key technical levels and volume spikes, with many citing the stock's low float as the primary catalyst for its rapid, multi-day price fluctuations.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is trending as investors react to positive Phase 3 clinical momentum and heavy institutional accumulation from notable funds, fueling speculation regarding a potential buyout or strategic partnership. Community discussion is dominated by the stock's significant move on high volume, with many focusing on the low effective float and the company's lack of debt as potential catalysts for further upward volatility.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently in focus following positive Phase 3 clinical trial results for its acne treatment in China, which has sparked optimism regarding its licensing strategy and potential U.S. development pathways. Investors are closely monitoring its MASH pipeline and combination therapy efforts, viewing the company as a significantly undervalued acquisition target relative to the billions of dollars in TAM across its therapeutic indications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medical Stocks To Research - January 9th

Eli Lilly and Company, Novo Nordisk A/S, Revolution Medicines, Thermo Fisher Scientific, UnitedHealth Group, Cidara Therapeutics, and Merck & Co., Inc. are the seven Medical stocks to watch today...

Biotech Stocks Worth Watching - January 8th

Cidara Therapeutics, Abivax, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

Merck to Complete Acquisition of Cidara Therapeutics

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of...

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Hold" from Analysts

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat.com...

Biotech Stocks To Follow Now - January 5th

Amicus Therapeutics, Danaher, argenex, Cidara Therapeutics, United Therapeutics, Vertex Pharmaceuticals, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock...

Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High - Here's Why

Cidara Therapeutics (NASDAQ:CDTX) Sets New 1-Year High - Here's Why...

Promising Biotech Stocks To Consider - January 4th

Danaher, Vertex Pharmaceuticals, Cidara Therapeutics, Moderna, and United Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...

Biotech Stocks To Watch Today - January 3rd

Danaher, Vertex Pharmaceuticals, Cidara Therapeutics, Moderna, United Therapeutics, argenex, and Abivax are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Top Biotech Stocks To Watch Now - January 2nd

Danaher, Moderna, and Cidara Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are publicly traded shares of companies that use...

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Key PointsHighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.79 million...

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

CDTX
Cidara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CDTX News

CDTXCidara Therapeutics Inc